Menu Menu


GLAXF Financials       Clear


GLAXF        0001131399    
Filing Date Form Type Description Document
2023-06-28 6-K GSK COMPLETES ACQUISITION OF BELLUS HEALTH View Document
2023-06-27 6-K FDA FAST TRACK FOR GONORRHOEA VACCINE CANDIDATE View Document
2023-06-26 6-K GSK DAPRODUSTAT GAINS POSITIVE EMA CHMP OPINION View Document
2023-06-26 6-K SHINGRIX APPROVED IN JAPAN FOR ADULTS 18 AND OVER View Document
2023-06-23 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2023-06-23 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2023-06-23 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2023-06-23 6-K STATEMENT: ZANTAC (RANITIDINE) LITIGATION View Document
2023-06-22 6-K GSKS AREXVY RECOMMENDED BY ACIP View Document
2023-06-21 11-K ANNUAL REPORT View Document
2023-06-21 11-K ANNUAL REPORT OF EMPLOYEE STOCK PURCHASE View Document
2023-06-21 6-K SEASON TWO DATA FOR GSK AREXVY RSV OA VACCINE View Document
2023-06-16 6-K EXTENSION OF FDA REVIEW PERIOD FOR MOMELOTINIB View Document
2023-06-12 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2023-06-07 6-K EU AUTHORISATION OF GSKS RSV VACCINE AREXVY View Document
2023-06-06 6-K GSK RECEIVES US FDA FILE ACCEPTANCE FOR JEMPERLI View Document
2023-06-01 6-K TOTAL VOTING RIGHTS View Document
2023-05-30 SD SPECIALIZED DISCLOSURE View Document
2023-05-22 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2023-05-16 SC 13D/A AMENDMENT TO FORM SC 13D View Document
2023-05-15 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2023-05-15 6-K BLOCK LISTING INTERIM REVIEW View Document
2023-05-12 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2023-05-12 6-K MENABCWY VACCINE PRELIMINARY PHASE III RESULTS View Document
2023-05-12 6-K STATEMENT: ZANTAC LITIGATION UPDATE BC CANADA View Document
2023-05-12 6-K GSK COMPLETES SALE OF SHARES IN HALEON PLC View Document
2023-05-12 6-K CURRENT REPORT OF FOREIGN ISSUER View Document
2023-05-09 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2023-05-04 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2023-05-03 6-K RESULT OF AGM View Document
2023-05-03 6-K US FDA APPROVES GSKS RSV VACCINE FOR OLDER ADULTS View Document
2023-05-02 6-K TOTAL VOTING RIGHTS View Document
2023-04-28 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2023-04-27 6-K GSK RSV OA VACCINE GAINS POSITIVE EMA CHMP OPINION View Document
2023-04-26 6-K 1ST QUARTER RESULTS View Document
2023-04-25 6-K EMA VALIDATES JEMPERLI FILING FOR NEW INDICATION View Document
2023-04-20 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2023-04-19 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2023-04-18 6-K GSK REACHES AGREEMENT TO ACQUIRE BELLUS HEALTH INC View Document
2023-04-17 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2023-04-17 6-K GEPOTIDACIN POSITIVE PHASE III DATA View Document
2023-04-17 20-F/A 20-F/A View Document
2023-04-03 6-K TOTAL VOTING RIGHTS View Document
2023-03-28 6-K POSITIVE PHASE III RUBY RESULTS FOR JEMPERLI View Document
2023-03-27 6-K PUBLICATION OF 2023 AGM NOTICE View Document
2023-03-24 6-K STATEMENT: ZANTAC (RANITIDINE) LITIGATION View Document
2023-03-21 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2023-03-20 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2023-03-15 EFFECT View Document
2023-03-14 6-K POSITIVE PHASE III RESULTS FOR MENABCWY VACCINE View Document
2023-03-14 6-K NUCALA NDA ACCEPTED FOR REVIEW IN CHINA View Document
2023-03-13 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2023-03-10 POS AM POS AM View Document
2023-03-10 6-K GSK ANNUAL REPORT 2022 ON FORM 20-F View Document
2023-03-10 IRANNOTICE IRANNOTICE View Document
2023-03-10 20-F 20-F View Document
2023-03-10 6-K GSK PUBLISHES ANNUAL REPORT 2022 View Document
2023-03-02 6-K FDA AD COM VOTES TO SUPPORT GSK RSV OA VACCINE View Document
2023-03-01 6-K TOTAL VOTING RIGHTS View Document
2023-02-27 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2023-02-23 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2023-02-23 6-K VIIV HEALTHCARE ANNOUNCES CABENUVA POSITIVE DATA View Document
2023-02-22 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2023-02-16 6-K NEJM PUBLISHES GSK RSV OA VACCINE CANDIDATE TRIAL View Document
2023-02-15 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2023-02-15 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2023-02-14 SC 13G/A SC 13G/A View Document
2023-02-14 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2023-02-14 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2023-02-14 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2023-02-14 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2023-02-10 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2023-02-10 6-K JEMPERLI FULL FDA APPROVAL FOLLOWING GARNET TRIAL View Document
2023-02-10 6-K JEMPERLI FDA ODAC POSITIVE OUTCOME View Document
2023-02-06 SC 13G SCHEDULE 13G View Document
2023-02-02 6-K DAPRODUSTAT APPROVED BY US FDA FOR ANAEMIA OF CKD View Document
2023-02-01 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2023-02-01 6-K TOTAL VOTING RIGHTS View Document
2023-02-01 6-K BENLYSTA GRANTED ORPHAN DRUG DESIGNATION BY US FDA View Document
2023-02-01 6-K FINAL RESULTS View Document
2023-01-30 SC 13G SCHEDULE 13G View Document
2023-01-30 3 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP View Document
2023-01-20 SC 13D/A AMENDMENT TO FORM SC 13D View Document
2023-01-20 SC 13D/A SCHEDULE 13D/A View Document
2023-01-18 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2023-01-17 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2023-01-17 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2023-01-13 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2023-01-12 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2023-01-03 6-K TOTAL VOTING RIGHTS View Document
2022-12-22 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2022-12-21 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2022-12-21 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2022-12-15 6-K BOARD AND COMMITTEE CHANGES View Document
2022-12-13 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2022-12-07 6-K STATEMENT: ZANTAC (RANITIDINE) LITIGATION View Document
2022-12-05 6-K TRANSFER OF TREASURY SHARES View Document
2022-12-02 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2022-12-02 6-K JEMPERLI POSITIVE TRIAL IN ENDOMETRIAL CANCER View Document
2022-12-02 6-K EMA FILE ACCEPTED FOR MOMELOTINIB View Document

Find registration statements, periodic reports, and other forms by typing ticker symbol of a company.

Ticker:

Search company filings and access detailed reports including 10-K, 10-Q, 8-K, and other critical filings. Stay informed on corporate disclosures, regulatory filings, and updates with our easy-to-use EDGAR API filings search tool.



We can also help with your taxes.

Formal Tax

www.formal.tax





(402) 804-8293


Formal Financial App
Google Play - Apple Store

created using: Admin Canvas